

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 879 888 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

25.11.1998 Bulletin 1998/48

(51) Int Cl.⁶: **C12N 15/12, C07K 14/705,
C12Q 1/68, A61K 31/70,
A61K 38/17, G01N 33/50,
G01N 33/68**

(21) Application number: **98303994.2**

(22) Date of filing: **20.05.1998**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:

AL LT LV MK RO SI

(30) Priority: **23.05.1997 GB 9710752**

19.03.1998 GB 9805954

(71) Applicant: **SMITHKLINE BEECHAM PLC**
Brentford, Middlesex TW8 9EP (GB)

(72) Inventors:

- **Kelsell, David P., SmithKline Beecham Pharm.**
Harlow, Essex CM19 5AW (GB)

- **Barnes, Michael R., SmithKline Beecham Pharm.**
Harlow, Essex CM19 5AW (GB)
- **Testa, Tanla Tamson,**
SmithKline Beecham Pharm.
Harlow, Essex CM19 5AW (GB)

(74) Representative: **Crump, Julian Richard John et al**
FJ Cleveland,
40-43 Chancery Lane
London WC2A 1JQ (GB)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) **Patched-2 polypeptides and polynucleotides and methods for their production**

(57) Patched-2 polypeptides and polynucleotides and methods for producing such polypeptides by recom-

binant techniques are disclosed. Also disclosed are methods for utilizing Patched-2 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

EP 0 879 888 A2

Description**Field of the Invention**

5 This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.

Background of the Invention

10 The drug discovery process is currently undergoing a fundamental revolution as it embraces 'functional genomics', that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on 'positional cloning'. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.

15 Functional genomics relies heavily on high throughput sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.

Summary of the Invention

20 The present invention relates to Patched-2, in particular Patched-2 polypeptides and Patched-2 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of particularly cancer, but also kidney diseases, cardiovascular diseases, stroke, inflammatory disorders, neurological disorders, including alzheimer's disease and mood disorders; developmental disorders, including Ptosis, hereinafter referred to as "the Diseases", amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with Patched-2 imbalance with the identified compounds.

30 In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate Patched-2 activity or levels.

Description of the Invention

35 In a first aspect, the present invention relates to Patched-2 polypeptides. Such peptides include isolated polypeptides comprising an amino acid sequence which has at least 92% identity, preferably at least 95% identity, more preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include those comprising the amino acid of SEQ ID NO:2.

40 Further peptides of the present invention include isolated polypeptides in which the amino acid sequence has at least 92% identity, preferably at least 95%, more preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2. Such polypeptides include the polypeptide of SEQ ID NO:2.

Further peptides of the present invention include isolated polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO: 1.

45 Polypeptides of the present invention are believed to be members of the Patched Receptor family of polypeptides. They are therefore of interest because members of the patched receptor family are known to be associated with a number of diseases. Dominant null mutations in Patched-1 in humans causes basal cell nevus syndrome and basal cell carcinomas, the commonest form of cancer (Johnson, et al, (1996) Science, 272:1668-1671). Mutations in the patched homologue, Npcl causes Niemann-Pick C, a cholesterol accumulation disorder. It seems likely therefore that mutations in Patched-2 may also cause cancers and cell proliferative disorders. Patched has been well characterised in *Drosophila* in terms of its involvement in Hedgehog signaling (Chen & Struhl (1996) Cell, 87:553-663). Other members of the patched protein family are believed to serve as transducer molecules for hedgehog signalling, this is likely in turn to influence Wnt signal transduction. This may be essential for normal morphogenesis and/or differentiated function in diverse tissues. Although the human Patched-2 protein is highly homologous to the mouse Patched-2 protein, the N-terminus is truncated by 490 amino acids, and the C-terminus by 166 amino acids, making human Patched-2 approximately half the size of mouse Patched-2. This truncation results in a protein with 4 transmembrane domains corresponding to TM5-8 of the 12 transmembrane domain mouse Patched-2 protein. This transmembrane structure corresponds closely to the second of the two large extracellular domains seen in patched proteins (Motoyama, et al, (1998) Nature Genet. 18: 104-106). This suggests a possible domain(s) duplication during the evolution of the mouse Patched-

50

55

2 protein.

These properties are hereinafter referred to as Patched-2 activity* or Patched-2 polypeptide activity* or "biological activity of Patched-2". Also included amongst these activities are antigenic and immunogenic activities of said Patched-2 polypeptides, in particular the antigenic and immunogenic activities of the polypeptide of SEQ ID NO:2. Preferably, a polypeptide of the present invention exhibits at least one biological activity of Patched-2.

Five single nucleotide polymorphisms (SNPs) in human Patched-2 have also been recorded in independent cDNA transcripts from different tissues (determined from clones isolated from Marathon-Ready™ double-stranded cDNAs). These SNPs are as follows:-

| | | |
|----|-----------------------|---|
| 10 | position 160: C to T | Pro to Thr: identified in hypothalamus; |
| | position 417: A to G | Glu to Glu: identified in hypothalamus; |
| | position 651: C to T | Ala to Ala: identified in adipocytes; |
| | position 1139: A to C | Glu to Asp: identified in adipocytes; |
| 15 | position 1232: A to G | Tyr to Cys: identified in leukaemia tissue. |

The association of the SNPs with the tissues indicated are not in any way intended to limit the scope of the invention. The apparently high level of variability in the Patched-2 coding sequence may indicate a high level of variation in the Patched-2 gene in the human population as a whole.

The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

In a further aspect, the present invention relates to Patched-2 polynucleotides. Such polynucleotides include isolated polynucleotides comprising a nucleotide sequence encoding a polypeptide which has at least 92% identity, preferably at least 95% to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2. In this regard, polypeptides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the nucleotide sequence contained in SEQ ID NO:1 encoding the polypeptide of SEQ ID NO:2.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence that has at least 90% identity, preferably at least 95% identity, to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, over the entire coding region. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred.

Further polynucleotides of the present invention include isolated polynucleotides comprising a nucleotide sequence which has at least 90% identity, preferably at least 95% identity, to SEQ ID NO: 1 over the entire length of SEQ ID NO: 1. In this regard, polynucleotides which have at least 97% identity are highly preferred, whilst those with at least 98-99% identity are more highly preferred, and those with at least 99% identity are most highly preferred. Such polynucleotides include a polynucleotide comprising the polynucleotide of SEQ ID NO:1 as well as the polynucleotide of SEQ ID NO:2.

The invention also provides polynucleotides which are complementary to all the above described polynucleotides.

The nucleotide sequence of SEQ ID NO: 1 shows homology with mouse Patched-2 (Motoyama, et al, (1998) Nature Genet. 18:104-106; GenBank accession No.AB010833). The nucleotide sequence of SEQ ID NO: 1 is a cDNA sequence and comprises a polypeptide encoding sequence (nucleotide 67 to 1656) encoding a polypeptide of 529 amino acids, the polypeptide of SEQ ID NO:2. The nucleotide sequence encoding the polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in SEQ ID NO: 1 or it may be a sequence other than the one contained in SEQ ID NO:1, which, as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The polypeptide of the SEQ ID NO:2 is structurally related to other proteins of the Patched Receptor family, having homology and/or structural similarity with mouse Patched-2 (Motoyama, et al, (1998) Nature Genet. 18:104-106; GenBank accession No.AB010833).

Preferred polypeptides and polynucleotides of the present invention are expected to have, *inter alia*, similar biological functions/properties to their homologous polypeptides and polynucleotides. Furthermore, preferred polypeptides and polynucleotides of the present invention have at least one Patched-2 activity.

The present invention also relates to partial or other polynucleotide and polypeptide sequences which were first identified prior to the determination of the corresponding full length sequences of SEQ ID NO: 1 and SEQ ID NO:2.

Accordingly, in a further aspect, the present invention provides for an isolated polynucleotide which:

- (a) comprises a nucleotide sequence which has at least 75% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;
- (b) has a nucleotide sequence which is at least 75% identity, preferably at least 80% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% identity, to SEQ ID NO:3 over the entire length of SEQ ID NO:3;
- (c) the polynucleotide of SEQ ID NO:3; or
- (d) a nucleotide sequence encoding a polypeptide which has at least 80% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4, over the entire length of the sequence of SEQ ID NO:4;

as well as the polynucleotide of SEQ ID NO:3.

The present invention further provides for a polypeptide which:

- (a) comprises an amino acid sequence which has at least 80% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% identity, to that of the amino acid sequence of SEQ ID NO:4 over the entire length of the sequence of SEQ ID NO:4;
- (b) has an amino acid sequence which is at least 80% identity, preferably at least 90% identity, more preferably at least 95% identity, most preferably at least 97-99% identity, to the amino acid sequence of SEQ ID NO:4 over the entire length of the sequence of SEQ ID NO:4;
- (c) comprises the amino acid sequence of SEQ ID NO:4; and
- (d) is the polypeptide of SEQ ID NO:4;

as well as polypeptides encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

The nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded thereby are derived from EST (Expressed Sequence Tag) sequences. It is recognised by those skilled in the art that there will inevitably be some nucleotide sequence reading errors in EST sequences (see Adams, M.D. *et al*, Nature 377 (supp) 3, 1995). Accordingly, the nucleotide sequence of SEQ ID NO:3 and the peptide sequence encoded therefrom are therefore subject to the same inherent limitations in sequence accuracy. Furthermore, the peptide sequence encoded by SEQ ID NO:3 comprises a region of identity or close homology and/or close structural similarity (for example a conservative amino acid difference) with the closest homologous or structurally similar protein.

Polynucleotides of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human neutrophils, using the expressed sequence tag (EST) analysis (Adams, M.D., *et al*, Science (1991) 252:1651-1656; Adams, M.D. *et al*, Nature, (1992) 355:632-634; Adams, M.D., *et al*, Nature (1995) 377 Supp:3-174). Polynucleotides of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

When polynucleotides of the present invention are used for the recombinant production of polypeptides of the present invention, the polynucleotide may include the coding sequence for the mature polypeptide, by itself; or the coding sequence for the mature polypeptide in reading frame with other coding sequences, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protein sequence, or other fusion peptide portions. For example, a marker sequence which facilitates purification of the fused polypeptide can be encoded. In certain preferred embodiments of this aspect of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al*, Proc Natl Acad Sci USA (1989) 86:821-824, or is an HA tag. The polynucleotide may also contain non-coding 5' and 3' sequences, such as transcribed, non-translated sequences, splicing and polyadenylation signals, ribosome binding sites and sequences that stabilize mRNA.

Further embodiments of the present invention include polynucleotides encoding polypeptide variants which comprise the amino acid sequence of SEQ ID NO:2 and in which several, for instance from 5 to 10, 1 to 5, 1 to 3, 1 to 2 or 1, amino acid residues are substituted, deleted or added, in any combination.

Polynucleotides which are identical or have sufficient percent identity to a nucleotide sequence contained in SEQ ID NO: 1, may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification (eg. PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention

and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO: 1. Typically these nucleotide sequences are 70% identical, preferably 80% identical, more preferably 90% identical, most preferably 95% identical to that of the referent. The probes or primers will generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof; and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10 % dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1xSSC at about 65°C. Thus the present invention also includes polynucleotides obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or a fragment thereof.

The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is short at the 5' end of the cDNA. This is a consequence of reverse transcriptase, an enzyme with inherently low 'processivity' (a measure of the ability of the enzyme to remain attached to the template during the polymerisation reaction), failing to complete a DNA copy of the mRNA template during 1 st strand cDNA synthesis.

There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the 'missing' 5' end of the cDNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using 'nested' primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the known gene sequence). The products of this reaction can then be analysed by DNA sequencing and a full-length cDNA constructed either by joining the product directly to the existing cDNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

Recombinant polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems which comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems and to the production of polypeptides of the invention by recombinant techniques. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention.

For recombinant production, host cells can be genetically engineered to incorporate expression systems or portions thereof for polynucleotides of the present invention. Introduction of polynucleotides into host cells can be effected by methods described in many standard laboratory manuals, such as Davis et al., Basic Methods in Molecular Biology (1986) and Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y. (1989). Preferred such methods include, for instance, calcium phosphate transfection, DEAE-dextran mediated transfection, transfection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic introduction or infection.

Representative examples of appropriate hosts include bacterial cells, such as *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells; and plant cells.

A great variety of expression systems can be used, for instance, chromosomal, episomal and virus-derived systems, e.g., vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression systems may contain control regions that regulate as well as engender expression. Generally, any system or vector which is able to maintain, propagate or express a polynucleotide to produce a polypeptide in a host may be used. The appropriate nucleotide sequence may be inserted into an expression system by any

of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (supra). Appropriate secretion signals may be incorporated into the desired polypeptide to allow secretion of the translated protein into the lumen of the endoplasmic reticulum, the periplasmic space or the extracellular environment. These signals may be endogenous to the polypeptide or they may be heterologous signals.

If a polypeptide of the present invention is to be expressed for use in screening assays, it is generally preferred that the polypeptide be produced at the surface of the cell. In this event, the cells may be harvested prior to use in the screening assay. If the polypeptide is secreted into the medium, the medium can be recovered in order to recover and purify the polypeptide. If produced intracellularly, the cells must first be lysed before the polypeptide is recovered.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, high performance liquid chromatography is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and or purification.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of the gene characterised by the polynucleotide of SEQ ID NO: 1 which is associated with a dysfunction will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease; which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva, tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled Patched-2 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, e.g., Myers *et al.*, Science (1985) 230:1242). Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S1 protection or the chemical cleavage method (see Cotton *et al.*, Proc Natl Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotide probes comprising Patched-2 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee *et al.*, Science, Vol 274, pp 610-613 (1996)).

The diagnostic assays offer a process for diagnosing or determining a susceptibility to the Diseases through detection of mutation in the Patched-2 gene by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR, RNase protection, Northern blotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO: 1, or a fragment thereof;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2 or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, particularly cancer, but also kidney diseases, cardiovascular diseases, stroke, inflammatory disorders, neurological disorders, including alzheimer's disease and mood disorders; developmental disorders, including Potosis, , amongst others.

The nucleotide sequences of the present invention are also valuable for chromosome localisation. The sequence is specifically targeted to, and can hybridize with, a particular location on an individual human chromosome. The mapping of relevant sequences to chromosomes according to the present invention is an important first step in correlating

those sequences with gene associated disease. Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found in, for example, V. McKusick, Mendelian Inheritance in Man (available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and diseases that have been mapped to the same chromosomal region are then identified through linkage analysis (coinheritance of physically adjacent genes). The gene of the present invention maps to human chromosome 1p34.1-p32.3.

The differences in the cDNA or genomic sequence between affected and unaffected individuals can also be determined. If a mutation is observed in some or all of the affected individuals but not in any normal individuals, then the mutation is likely to be the causative agent of the disease.

The nucleotide sequences of the present invention are also valuable for tissue localisation. Such techniques allow the determination of expression patterns of the Patched-2 polypeptides in tissues by detection of the mRNAs that encode them. These techniques include in situ hybridization techniques and nucleotide amplification techniques, for example PCR. Such techniques are well known in the art. Results from these studies provide an indication of the normal functions of the polypeptides in the organism. In addition, comparative studies of the normal expression pattern of Patched-2 mRNAs with that of mRNAs encoded by a mutant Patched-2 gene provide valuable insights into the role of mutant Patched-2 polypeptides, or that of inappropriate expression of normal Patched-2 polypeptides, in disease. Such inappropriate expression may be of a temporal, spatial or simply quantitative nature. The polypeptides of the invention or their fragments or analogs thereof, or cells expressing them, can also be used as immunogens to produce antibodies immunospecific for polypeptides of the present invention. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides in the prior art.

Antibodies generated against polypeptides of the present invention may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, using routine protocols. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., *Nature* (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozbor *et al.*, *Immunology Today* (1983) 4:72) and the EBV-hybridoma technique (Cole *et al.*, *Monoclonal Antibodies and Cancer Therapy*, 77-96, Alan R. Liss, Inc., 1985).

Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography.

Antibodies against polypeptides of the present invention may also be employed to treat the Diseases, amongst others.

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

Another aspect of the invention relates to a method for inducing an immunological response in a mammal which comprises inoculating the mammal with a polypeptide of the present invention, adequate to produce antibody and/or T cell immune response to protect said animal from the Diseases hereinbefore mentioned, amongst others. Yet another aspect of the invention relates to a method of inducing immunological response in a mammal which comprises, delivering a polypeptide of the present invention via a vector directing expression of the polynucleotide and coding for the polypeptide *in vivo* in order to induce such an immunological response to produce antibody to protect said animal from diseases.

A further aspect of the invention relates to an immunological/vaccine formulation (composition) which, when introduced into a mammalian host, induces an immunological response in that mammal to a polypeptide of the present invention wherein the composition comprises a polypeptide or polynucleotide of the present invention. The vaccine formulation may further comprise a suitable carrier. Since a polypeptide may be broken down in the stomach, it is preferably administered parenterally (for instance, subcutaneous, intramuscular, intravenous, or intradermal injection). Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of

the recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

Polypeptides of the present invention are responsible for one or more biological functions, including one or more disease states, in particular the Diseases hereinbefore mentioned. It is therefore desirable to devise screening methods to identify compounds which stimulate or which inhibit the function of the polypeptide. Accordingly, in a further aspect, the present invention provides for a method of screening compounds to identify those which stimulate or which inhibit the function of the polypeptide. In general, agonists or antagonists may be employed for therapeutic and prophylactic purposes for such Diseases as hereinbefore mentioned. Compounds may be identified from a variety of sources, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. Such agonists, antagonists or inhibitors so-identified may be natural or modified substrates, ligands, receptors, enzymes, etc., as the case may be, of the polypeptide; or may be structural or functional mimetics thereof (see Coligan *et al.*, Current Protocols in Immunology 1(2):Chapter 5 (1991)).

The screening method may simply measure the binding of a candidate compound to the polypeptide, or to cells or membranes bearing the polypeptide, or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptides may be employed in screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide of the present invention, to form a mixture, measuring Patched-2 activity in the mixture, and comparing the Patched-2 activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and Patched-2 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists for the polypeptide of the present invention (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

The polynucleotides, polypeptides and antibodies to the polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

The polypeptide may be used to identify membrane bound or soluble receptors, if any, through standard receptor binding techniques known in the art. These include, but are not limited to, ligand binding and crosslinking assays in which the polypeptide is labeled with a radioactive isotope (for instance, ^{125}I), chemically modified (for instance, biotinylated), or fused to a peptide sequence suitable for detection or purification, and incubated with a source of the putative receptor (cells, cell membranes, cell supernatants, tissue extracts, bodily fluids). Other methods include biophysical techniques such as surface plasmon resonance and spectroscopy. These screening methods may also be used to identify agonists and antagonists of the polypeptide which compete with the binding of the polypeptide to its receptors, if any. Standard methods for conducting such assays are well understood in the art.

Examples of potential polypeptide antagonists include antibodies or, in some cases, oligonucleotides or proteins which are closely related to the ligands, substrates, receptors, enzymes, etc., as the case may be, of the polypeptide, e.g., a fragment of the ligands, substrates, receptors, enzymes, etc.; or small molecules which bind to the polypeptide of the present invention but do not elicit a response, so that the activity of the polypeptide is prevented.

Thus, in another aspect, the present invention relates to a screening kit for identifying agonists, antagonists, ligands, receptors, substrates, enzymes, etc. for polypeptides of the present invention; or compounds which decrease or enhance the production of such polypeptides, which comprises:

- (a) a polypeptide of the present invention;
- (b) a recombinant cell expressing a polypeptide of the present invention;
- (c) a cell membrane expressing a polypeptide of the present invention; or
- (d) antibody to a polypeptide of the present invention;

which polypeptide is preferably that of SEQ ID NO:2.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component.

It will be readily appreciated by the skilled artisan that a polypeptide of the present invention may also be used in a method for the structure-based design of an agonist, antagonist or inhibitor of the polypeptide, by:

- 5 (a) determining in the first instance the three-dimensional structure of the polypeptide;
- (b) deducing the three-dimensional structure for the likely reactive or binding site(s) of an agonist, antagonist or inhibitor;
- (c) synthesizing candidate compounds that are predicted to bind to or react with the deduced binding or reactive site; and
- 10 (d) testing whether the candidate compounds are indeed agonists, antagonists or inhibitors.

It will be further appreciated that this will normally be an iterative process.

In a further aspect, the present invention provides methods of treating abnormal conditions such as, for instance, particularly cancer, but also kidney diseases, cardiovascular diseases, stroke, inflammatory disorders, neurological disorders, including alzheimers disease and mood disorders; developmental disorders, including Ptois, , related to either an excess of, or an under-expression of, Patched-2 polypeptide activity.

If the activity of the polypeptide is in excess, several approaches are available. One approach comprises administering to a subject in need thereof an inhibitor compound (antagonist) as hereinabove described, optionally in combination with a pharmaceutically acceptable carrier, in an amount effective to inhibit the function of the polypeptide, 20 such as, for example, by blocking the binding of ligands, substrates, receptors, enzymes, etc., or by inhibiting a second signal, and thereby alleviating the abnormal condition. In another approach, soluble forms of the polypeptides still capable of binding the ligand, substrate, enzymes, receptors, etc. in competition with endogenous polypeptide may be administered. Typical examples of such competitors include fragments of the Patched-2 polypeptide.

In still another approach, expression of the gene encoding endogenous Patched-2 polypeptide can be inhibited 25 using expression blocking techniques. Known such techniques involve the use of antisense sequences, either internally generated or externally administered (see, for example, O'Connor, J Neurochem (1991) 56:560 in Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988)). Alternatively, oligonucleotides which form triple helices ("triplexes") with the gene can be supplied (see, for example, Lee *et al.*, Nucleic Acids Res (1979) 6:3073; Cooney *et al.*, Science (1988) 241:456; Dervan *et al.*, Science (1991) 251:1360). These oligomers can 30 be administered *per se* or the relevant oligomers can be expressed *in vivo*. Synthetic antisense or triplex oligonucleotides may comprise modified bases or modified backbones. Examples of the latter include methylphosphonate, phosphorothioate or peptide nucleic acid backbones. Such backbones are incorporated in the antisense or triplex oligonucleotide in order to provide protection from degradation by nucleases and are well known in the art. Antisense and triplex molecules synthesised with these or other modified backbones also form part of the present invention.

In addition, expression of the Patched-2 polypeptide may be prevented by using ribozymes specific to the Patched-2 mRNA sequence. Ribozymes are catalytically active RNAs that can be natural or synthetic (see for example Usman, N, *et al.*, Curr. Opin. Struct. Biol (1996) 6(4), 527-33.) Synthetic ribozymes can be designed to specifically cleave Patched-2 mRNAs at selected positions thereby preventing translation of the Patched-2 mRNAs into functional polypeptide. Ribozymes may be synthesised with a natural ribose phosphate backbone and natural bases, as normally 40 found in RNA molecules. Alternatively the ribozymes may be synthesised with non-natural backbones to provide protection from ribonuclease degradation, for example, 2'-O-methyl RNA, and may contain modified bases.

For treating abnormal conditions related to an under-expression of Patched-2 and its activity, several approaches are also available. One approach comprises administering to a subject a therapeutically effective amount of a compound which activates a polypeptide of the present invention, i.e., an agonist as described above, in combination with a 45 pharmaceutically acceptable carrier, to thereby alleviate the abnormal condition. Alternatively, gene therapy may be employed to effect the endogenous production of Patched-2 by the relevant cells in the subject. For example, a polynucleotide of the invention may be engineered for expression in a replication defective retroviral vector, as discussed above. The retroviral expression construct may then be isolated and introduced into a packaging cell transduced with a retroviral plasmid vector containing RNA encoding a polypeptide of the present invention such that the packaging 50 cell now produces infectious viral particles containing the gene of interest. These producer cells may be administered to a subject for engineering cells *in vivo* and expression of the polypeptide *in vivo*. For an overview of gene therapy, see Chapter 20, Gene Therapy and other Molecular Genetic-based Therapeutic Approaches, (and references cited therein) in Human Molecular Genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996). Another approach is to administer a therapeutic amount of a polypeptide of the present invention in combination with a suitable 55 pharmaceutical carrier.

In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide, such as the soluble form of a polypeptide of the present invention, agonist/antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such

carriers include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. Polypeptides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, and the like.

The dosage range required depends on the choice of peptide or other compounds of the present invention, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 $\mu\text{g/kg}$ of subject. Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

Polypeptides used in treatment can also be generated endogenously in the subject, in treatment modalities often referred to as "gene therapy" as described above. Thus, for example, cells from a subject may be engineered with a polynucleotide, such as a DNA or RNA, to encode a polypeptide *ex vivo*, and for example, by the use of a retroviral plasmid vector. The cells are then introduced into the subject.

Polynucleotide and polypeptide sequences form a valuable information resource with which to identify further sequences of similar homology. This is most easily facilitated by storing the sequence in a computer readable medium and then using the stored data to search a sequence database using well known searching tools, such as those in the GCG and Lasergene software packages. Accordingly, in a further aspect, the present invention provides for a computer readable medium having stored thereon a polynucleotide comprising the sequence of SEQ ID NO: 1 and/or a polypeptide sequence encoded thereby.

The following definitions are provided to facilitate understanding of certain terms used frequently hereinbefore.

"Antibodies" as used herein includes polyclonal and monoclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, including the products of an Fab or other immunoglobulin expression library.

"Isolated" means altered "by the hand of man" from the natural state. If an "isolated" composition or substance occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living animal is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein.

"Polynucleotide" generally refers to any polyribonucleotide or polydeoxiribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. "Polynucleotides" include, without limitation, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The term "polynucleotide" also includes DNAs or RNAs containing one or more modified bases and DNAs or RNAs with backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications may be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically or metabolically modified forms of polynucleotides as typically found in nature, as well as the chemical forms of DNA and RNA characteristic of viruses and cells. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.

"Polypeptide" refers to any peptide or protein comprising two or more amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres. "Polypeptide" refers to both short chains, commonly referred to as peptides, oligopeptides or oligomers, and to longer chains, generally referred to as proteins. Polypeptides may contain amino acids other than the 20 gene-encoded amino acids. "Polypeptides" include amino acid sequences modified either by natural processes, such as post-translational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more detailed monographs, as well as in a voluminous research literature. Modifications may occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present to the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched as a result of ubiquitination, and

they may be cyclic, with or without branching. Cyclic, branched and branched cyclic polypeptides may result from post-translation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, biotinylation covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination (see, for instance, *Proteins - Structure and Molecular Properties*, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York, 1993; Wold, F., *Post-translational Protein Modifications: Perspectives and Prospects*, pgs. 1-12 in *Post-translational Covalent Modification of Proteins*, B. C. Johnson, Ed., Academic Press, New York, 1983; Seifter *et al.*, "Analysis for protein modifications and nonprotein cofactors", *Meth Enzymol* (1990) 182: 626-646 and Rattan *et al.*, "Protein Synthesis: Post-translational Modifications and Aging", *Ann NY Acad Sci* (1992) 663:48-62).

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis techniques or by direct synthesis.

"Identity," as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988)). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., *et al.*, *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Altschul, S.F. *et al.*, *J. Molec. Biol.* 215: 403-410 (1990)). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., *et al.*, NCBI NLM NIH Bethesda, MD 20894; Altschul, S., *et al.*, *J. Mol. Biol.* 215: 403-410 (1990)). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

- 1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)
- Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad. Sci. USA*. 89:10915-10919 (1992)
- Gap Penalty: 12
- Gap Length Penalty: 4

A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

- 1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)
- Comparison matrix: matches = +10, mismatch = 0
- Gap Penalty: 50

Gap Length Penalty: 3 Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO: 1, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO: 1 by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO: 1, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein n_n is the number of nucleotide alterations, x_n is the total number of nucleotides in SEQ ID NO: 1, and y is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, etc., and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

Similarly, a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \cdot y),$$

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2; and y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

"Homolog" is a generic term used in the art to indicate a polynucleotide or polypeptide sequence possessing a high degree of sequence relatedness to a subject sequence. Such relatedness may be quantified by determining the degree of identity and/or similarity between the sequences being compared as hereinbefore described.

Falling within this generic term are the terms "ortholog", meaning a polynucleotide or polypeptide that is the functional equivalent of a polynucleotide or polypeptide in another species, and "paralog" meaning a functionally similar sequence when considered within the same species. Hence in the rat, for example, a member of the family of serotonin receptors is a paralog of the other members of the rat serotonin receptor family.

"Fusion protein" refers to a protein encoded by two, often unrelated, fused genes or fragments thereof. In one example, EP-A-0 464 discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, employing an immunoglobulin Fc region as a part of a fusion protein is advantageous for use in therapy and diagnosis resulting in, for example, improved pharmacokinetic properties [see, e.g., EP-A 0232 262]. On the other hand, for some uses it would be desirable to be able to delete the Fc part after the fusion protein has been expressed, detected and purified.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

SEQUENCE INFORMATION

SEQ ID NO:1

5 CCACTTTGACACGGCCCCCTCCCTTGTGACCTGAGGGCAGGTCCCCACTCTGTCTGGCAGGAGCGCATGGGC
 GAGTGTCTGCAGCGCACGGGCACCAGTGTCTGACTCAGATCCATCAACAACATGGCCGCCCTTCCTCATGGCT
 GCCCTCGTTCCCATCCCTGCGCTGCGAGCCTTCTCCCTACAGGCGGCCATAGTGGTTGGCTGCACCTTTGTA
 10 GCCGTGATGCTTGTCTTCCCAGCCATCCTCAGCCTGGACCTACGGCGGCGCCACTGCCAGCGCCTTGATGTG
 CTCTGCTGCTTCTCAGTCCCTGCTCTGCTCAGGTGATTGAGATCCTGCCCCAGGAGCTGGGGGACGGGACA
 GTACCAGTGGGCATTGCCACCTCACTGCCACAGTTCAAGCCTTTACCCACTGTGAAGCCAGCAGCCAGCAT
 GTGGTCACCATCCTGCTCCCAAGCCACCTGGTGCCCCACCTTCTGACCCACTGGGCTCTGAGCTCTTC
 15 AGCCCTGGAGGGTCCACACGGGACCTTCTAGGCCAGGAGGAGAGACAAGGCAGAAGGCAGCCTGCAAGTCC
 CTGCCCTGTGCCCGCTGGAATCTTGCCCATTTGCCCGCTATCAGTTTGGCCCGTTGCTGCTCCAGTCACAT
 GCCAAGGCCATCGTCTGGTGTCTTTGGTGTCTTCTGGGCTGAGCCTCTACGGAGCCACCTTGGTGCAA
 20 GACGGCCTGGCCCTGACGGATGTGGTGCCTCGGGGCACCAAGGAGCATGCCTTCTGAGCGCCAGCTCAGG
 TACTTCTCCCTGTACGAGGTGGCCCTGGTGACCCAGGCTGGCTTGTACTACGCCCACTCCCAACGCGCCCTC
 TTTGATCTGCACACGCGCTTCAGTTCCCTCAAGCGGTGCTGCCCCACCGGCCACCCAGGCACCCCGCACC
 25 TGGCTGCACTATTACCGCAACTGGCTACAGGAATCCAGGCTGCCTTTGACCAGGACTGGGCTTCTGGGCGC
 ATCACCCGCCACTCGTACCGCAATGGCTCTGAGGATGGGGCCCTGGCCTACAAGCTGCTCATCCAGACTGGA
 GACGCCCAGGAGCCTCTGGATTTAGCCAGCTGACCACAAGGAAGCTGGTGGACAGAGGGGACTGATTCCA
 CCCGAGCTCTTCTACATGGGGCTGACCGTGTGGGTGAGCAGTGACCCCTGGGTCTGGCAGCCTCACAAGGCC
 30 AACTTCTACCCCCACCTCCTGAATGGCTGCACGACAAATACGACACCACGGGGGAGAACCTTCGCATCCCG
 CCAGCTCAGCCCTTGGAGTTTGCCAGTTCCCTTCTGCTGCGTGGCCTCCAGAAGACTGCAGACTTTGTG
 GAGGCCATCGAGGGGGCCCGGGCAGCATGCGCAGAGGCCCGGCCAGGCTGGGGTGACGCCTACCCAGCGGC
 35 TCCCCCTTCTCTTCTGGGAACAGTATCTGGGCTGCGGCGCTGCTTCTGCTGGCCGTCTGCATCCTGCTG
 GTGTGCACTTTCTCTGCTGTGCTCTGCTGCTCCTCAACCCCTGGATGGCTGGCCTCATAGTGAAGTGTGCTG
 AGGAGTGGGGACAGAGACACCCACCCCTTCCCTGCCCAGCCTGTATCCCTCCTGCCAGGAGCCCTCTGTGA
 40 GCCCTGTCTCCCTCAGGTGCTGGTCTGCGGATGATGACAGTGGAACTCTTTGGTATCATGGGATCCCTGGA
 CATCAAGCTGAGTGCCATCCCCGTGGTGATCCTTGTGGCCTCTGTAGGCATTGGCGTTGAGTTACAGTCCA
 CGTGGCTCTGGTGAGCACGGGCATCCCGGGAGGGACCAATCAGCTGATTGAGTATTCAACACATATTGTTT
 AAGCCCCCTACTATGTGCTAGGTACTATTAAAGAAATTGGGCTGGGTGGACGTGGTGGCTATTCTGTAGTC
 45 CCAGCGCTTTGGGAGGCCGAGGCGGGTGGATACCTGAGGTAGGAAGTTCGAGACCAGCCTGGCCAACATGGT
 GAAACCCCTTGTCTTGA

SEQ ID NO:2

50 MGECLQRTGTSVVLTSINNMAAFLMAALVPIPALRAFSLQAAIVVGCTFVAVMLVFPAILSLDLRRRHCRQL
 DVLCCFSSPCSAQVIQILPQELGDGTVPGIAHLTATVQAFTHCEASSQHVVITLPPQAHLVPPPSDPLGSE
 LFSPPGGSTRDLLGQEEETRQKAACKSLPCARWNLAHPARYQFAPLLLQSHAKAIVLVLFGLLGLSLYGATL
 55 VQDGLALTDVVPRTKEHAFLSAQLRYFSLYEVALVTQGGFDYAHSQRALFDLHQRFSSSLKAVLPPPATQAP

RTWLHYRNLQGIQAAFDQDASGRITRHSYRNGSEDGALAYKLLIQTDGAEPLDFSQLTTRKLVDRGL
 IPPPELFYMGTLTVWVSSDPLGLAASQANFYPPPEWLHDKYDTTGENLRIPPAQPLEFAQFPFLRGLQKTAD
 FVEAIEGARAACAEAGQAGVHAYPSGSPFLFWEQVLGLRRCFLLAVCILLVCTFLVCALLLNPNWMAGLIVS
 ACRSGDRDTPPFPAQFVIPPARSPL

SEQ ID NO:3

ctgtcctggcaggagcgcatggcgagtgctgcagcgacgggcaccagtgtcgtactcacatccatcaac
 aacatggccgccttcctcatggctgccctcggtcccatccctgcgtgcgagccttctccctacag

SEQ ID NO:4

Blastx Output

DB Lookup gnl|PID|e254399

Gene Name (X98883) patched protein [Danio rerio]

Strand

| | | | | | | |
|---------------------------|----------|------|-----------------|---------|------------|-----|
| Score | 180 Bits | 82.8 | Query Seq Start | 83 End | 220 Length | 138 |
| Blast Poisson Probability | 3.5e-32 | | DB Seq Start | 512 End | 557 Length | 46 |

Identity 35 / 46 = 76.09%
 Positives 41 / 46 = 89.13%

Relative Position of Alignment:

1 |-----| 436

HNfir49:

1 LSMQERNGECLQRTGTSVVLTSINNMAFLMAALVPIPALRAFSLQ 46

+ ++ER G+CL+RTGTSV LTS+NNM AF MAALVPIPALRAFSLQ

Patched (Danio rerio): 512 IPPKERTGDCLRRRTGTSVALTSVNNMIAFFMAALVPIPALRAFSLQ 557

SEQ ID NO:4 refers to sequence labelled HNfir49

Annex to the description

5

SEQUENCE LISTING

(1) GENERAL INFORMATION

10

(i) APPLICANT: SmithKline Beecham plc

(ii) TITLE OF THE INVENTION: Novel compounds

15

(iii) NUMBER OF SEQUENCES: 4

20

(iv) CORRESPONDENCE ADDRESS

(A) ADDRESSEE: SmithKline Beecham

(B) STREET: New Horizons Court, Great West Road

(C) CITY: Brentford

25

(D) STATE:

(E) COUNTRY: UK

(F) ZIP: TW8 9ET

30

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette

(B) COMPUTER: IBM Compatible

(C) OPERATING SYSTEM: DOS

35

(D) SOFTWARE: FastSEQ for Windows Version 2.0

(vi) CURRENT APPLICATION DATA:

40

(A) APPLICATION NUMBER

(B) FILING DATE:

(C) CLASSIFICATION:

45

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER

(B) FILING DATE:

50

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Connell, Chris

55

(B) REGISTRATION NUMBER

(C) REFERENCE/DOCKET NUMBER: GH30311

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 0181-9752000

(B) TELEFAX: 0181-9756294

(C) TELEX:

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2032 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION SEQ ID NO: 1:

CCACTTGAC ACGCCCCCTC CTTGTGACC TGAGGGCAGG TCCCCACTCT GTCTGGCAG 60
 GAGCGCATGG GCGAGTGTCT GCAGGCAAG GGCAACAGTG TCGTACTCAC ATCCATCAAC 120
 AACATGGCG CTTCTCAT GGCTGCCCTC GTTCCCATCC CTGGGCTGG AGCCTTCTCC 180
 CTACAGGGG CCATAGTGGT TGGCTGCACC TTTGTAGCG TGATGCTGT CTTCCAGCC 240
 ATCCTCAGCC TGGACCTAAG GCGGCGCAC TGCCAGCGCC TTGATGTGCT CTGCTGCTT 300
 TCCAGTCCCT GCTCTGCTCA GGTGATTAG ATCCTGCCCC AGGAGCTGGG GGAOGGGACA 360
 GTACCACTGG GCATTGCCCA CTTCACTGCC ACAGTCAAG CCTTACCCA CTGTGAAGCC 420
 AGCAGCCAGC ATGTGGTCA CATCCTGCC CCCCAGCCC ACCTGGTGCC CCCACCTCT 480
 GACCCACTGG GCTCTGAGCT CTTAGCCCT GGAGGGCCA CAOGGACCT TCTAGGCCAG 540
 GAGGAGGAGA CAAGGCAGAA GGCAGCCTGC AAGTCCCTGC CTTGTGCCCG CTGGAATCTT 600
 GCCCATTTG CCGCTATCA GTTGCCCCG TTGCTGCTCC AGTCAATGC CAAGGCCATC 660
 GTGCTGGTGC TCTTGGTGC TCTCTGGGC CTGAGCCTCT AOGGAGCCAC CTTGGTGCAA 720
 GAOGGCTGG CCTGAOGGA TGTGGTGCCT OGGGGACCA AGGAGCATGC CTTCTGAGC 780
 GCCCAGCTCA GGTACTTCTC CTTGTAAGAG GTGGCCCTGG TGACCCAGGG TGGCTTTGAC 840
 TAGGCCACT CCCAAGCGC CTTCTTGAT CTGACCAAGC GCTCAGTTC CTTCAAGGCG 900
 GTGCTGCCCG CACCGGCCAC CCAGGCACCC CGCCTGGC TGCACTATTA CGCAACTGG 960
 CTACAGGGAA TCCAGGCTGC CTTGACCAG GACTGGGCTT CTGGGCGCAT CACCGGCCAC 1020
 TCGTACGCA ATGGCTCTGA GGATGGGGCC CTGGCCTACA AGCTGCTCAT CCAGACTGGA 1080
 GAOGCCAGG AGCCTCTGGA TTTAGCCAG CTGACCACAA GGAAGCTGGT GGACAGAGAG 1140
 GGACTGATT CACCGAGCT CTTCTACATG GGGCTGACG TGTGGGTGAG CAGTGACCCC 1200
 CTGGGTCTGG CAGCTCACA GGCCAATT C TACCCCCAC CTCTGAATG GCTGCACGAC 1260
 AATAAGACA CCAOGGGGA GAACCTGCG ATCCGCCAG CTAGCCCTT GGAGTTTGCC 1320

EP 0 879 888 A2

5 CAGTCCCCCT TCCTGCTGCG TGGCCTCCAG AAGACTGCAG ACTTTGTGGA GGCCATOGAG 1380
 GGGGCCCGGG CAGCATGCGC AGAGGCGGGC CAGGCTGGGG TGCAOGCCTA CCCCAGOGGC 1440
 TCCCCCTTCC TCTTCTGGGA ACAGTATCTG GGCTGOGGC GCTGCTTCT GCTGGCGCTC 1500
 TGCATCCTGC TGGTGTGCAC TTTCTCGTC TGTGCTCTGC TGCTCCTCAA CCCCTGGATG 1560
 GCTGGCCTCA TAGTGAGTGC TTGCAGGAGT GGGGACAGAG ACACCCCAACC CTTCCCTGCC 1620
 CAGCCTGTCA TCCCTCCTGC CAGGAGCCCT CTGTGAGCCC TGTCTCCCTC AGGTGCTGGT 1680
 CCTGGOGATG ATGACAGTGG AACTCTTTGG TATCATGGGA TCCCTGGACA TCAAGCTGAG 1740
 TGCCATCCCC GTGGTGATCC TTGTGGCCTC TGTAGGCATT GGOGTTGAGT TCACAGTCCA 1800
 CGTGGCTCTG GTGAGCAOGG GCATCCOGGG GAGGGACCAA TCAGCTGATT CAGTATTCAA 1860
 CACATATTGT TCAAGCCCCT ACTATGTGCT AGGTACTATT TAAGAATTTG GGCTGGGTGG 1920
 15 ACGTGGTGGC TCATTCCTGT AGTCCAGOG CTTTGGGAGG COGAGGOGGG TGGATACCTG 1980
 AGGTAGGAAG TTGAGACCA GCCTGGCCAA CATGCTGAAA CCCTTGTCTT TA 2032

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS

(A) LENGTH: 529 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

35 Met Gly Glu Cys Leu Gln Arg Thr Gly Thr Ser Val Val Leu Thr Ser
 1 5 10 15
 Ile Asn Asn Met Ala Ala Phe Leu Met Ala Ala Leu Val Pro Ile Pro
 20 25 30
 40 Ala Leu Arg Ala Phe Ser Leu Gln Ala Ala Ile Val Val Gly Cys Thr
 35 40 45
 Phe Val Ala Val Met Leu Val Phe Pro Ala Ile Leu Ser Leu Asp Leu
 50 55 60
 45 Arg Arg Arg His Cys Gln Arg Leu Asp Val Leu Cys Cys Phe Ser Ser
 65 70 75 80
 Pro Cys Ser Ala Gln Val Ile Gln Ile Leu Pro Gln Glu Leu Gly Asp
 85 90 95
 50 Gly Thr Val Pro Val Gly Ile Ala His Leu Thr Ala Thr Val Gln Ala
 100 105 110
 Phe Thr His Cys Glu Ala Ser Ser Gln His Val Val Thr Ile Leu Pro
 55 115 120 125

EP 0 879 888 A2

Pro Gln Ala His Leu Val Pro Pro Pro Ser Asp Pro Leu Gly Ser Glu
130 135 140

5 Leu Phe Ser Pro Gly Gly Ser Thr Arg Asp Leu Leu Gly Gln Glu Glu
145 150 155 160

Glu Thr Arg Gln Lys Ala Ala Cys Lys Ser Leu Pro Cys Ala Arg Trp
165 170 175

10 Asn Leu Ala His Phe Ala Arg Tyr Gln Phe Ala Pro Leu Leu Leu Gln
180 185 190

Ser His Ala Lys Ala Ile Val Leu Val Leu Phe Gly Ala Leu Leu Gly
195 200 205

15 Leu Ser Leu Tyr Gly Ala Thr Leu Val Gln Asp Gly Leu Ala Leu Thr
210 215 220

Asp Val Val Pro Arg Gly Thr Lys Glu His Ala Phe Leu Ser Ala Gln
225 230 235 240

20 Leu Arg Tyr Phe Ser Leu Tyr Glu Val Ala Leu Val Thr Gln Gly Gly
245 250 255

Phe Asp Tyr Ala His Ser Gln Arg Ala Leu Phe Asp Leu His Gln Arg
260 265 270

25 Phe Ser Ser Leu Lys Ala Val Leu Pro Pro Pro Ala Thr Gln Ala Pro
275 280 285

Arg Thr Trp Leu His Tyr Tyr Arg Asn Trp Leu Gln Gly Ile Gln Ala
290 295 300

30 Ala Phe Asp Gln Asp Trp Ala Ser Gly Arg Ile Thr Arg His Ser Tyr
305 310 315 320

Arg Asn Gly Ser Glu Asp Gly Ala Leu Ala Tyr Lys Leu Leu Ile Gln
325 330 335

35 Thr Gly Asp Ala Gln Glu Pro Leu Asp Phe Ser Gln Leu Thr Thr Arg
340 345 350

Lys Leu Val Asp Arg Glu Gly Leu Ile Pro Pro Glu Leu Phe Tyr Met
355 360 365

40 Gly Leu Thr Val Trp Val Ser Ser Asp Pro Leu Gly Leu Ala Ala Ser
370 375 380

45 Gln Ala Asn Phe Tyr Pro Pro Pro Pro Glu Trp Leu His Asp Lys Tyr
385 390 395 400

Asp Thr Thr Gly Glu Asn Leu Arg Ile Pro Pro Ala Gln Pro Leu Glu
405 410 415

50 Phe Ala Gln Phe Pro Phe Leu Leu Arg Gly Leu Gln Lys Thr Ala Asp
420 425 430

Phe Val Glu Ala Ile Glu Gly Ala Arg Ala Ala Cys Ala Glu Ala Gly
435 440 445

55 Gln Ala Gly Val His Ala Tyr Pro Ser Gly Ser Pro Phe Leu Phe Trp

EP 0 879 888 A2

450 455 460
 Glu Gln Tyr Leu Gly Leu Arg Arg Cys Phe Leu Leu Ala Val Cys Ile
 465 470 475 480
 5 Leu Leu Val Cys Thr Phe Leu Val Cys Ala Leu Leu Leu Leu Asn Pro
 485 490 495
 Trp Met Ala Gly Leu Ile Val Ser Ala Cys Arg Ser Gly Asp Arg Asp
 10 500 505 510
 Thr Pro Pro Phe Pro Ala Gln Pro Val Ile Pro Pro Ala Arg Ser Pro
 515 520 525
 15 Leu

(2) INFORMATION FOR SEQ ID NO: 3:

20 (i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 138 base pairs
 (B) TYPE: nucleic acid
 25 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

35 CTGTCCTGGC AGGAGCGCAT GGGGAGTGT CTGCAGGCA CGGGCACCAG TGTCGTACTC 60
 ACATCCATCA ACAACATGGC CGCCTTCCTC ATGGCTGCCC TCGTCCCAT CCCTGGGCTG 120
 CGAGCCTTCT CCCTACAG 138

(2) INFORMATION FOR SEQ ID NO: 4:

40

(i) SEQUENCE CHARACTERISTICS
 (A) LENGTH: 46 base pairs
 45 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

50

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

55 LSWQERMGEC LQRTGTSVVL TSINNMAAFL MAALVPIPAL RAFLSQ 46

5

SEQUENCE LISTING

10

(1) GENERAL INFORMATION

(i) APPLICANT: SmithKline Beecham plc

15

(ii) TITLE OF THE INVENTION: Novel compounds

20

(iii) NUMBER OF SEQUENCES: 4

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: SmithKline Beecham

(B) STREET: New Horizons Court, Great West Road

25

(C) CITY: Brentford

(D) STATE:

(E) COUNTRY: UK

(F) ZIP: TW8 9ET

30

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette

(B) COMPUTER: IBM Compatible

35

(C) OPERATING SYSTEM: DOS

(D) SOFTWARE: FastSEQ for Windows Version 2.0

40

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

45

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE:

50

(viii) ATTORNEY/AGENT INFORMATION:

55

5 (A) NAME: Connell, Chris
 (B) REGISTRATION NUMBER:
 (C) REFERENCE/DOCKET NUMBER: GH30311

10 (ix) TELECOMMUNICATION INFORMATION:
 (A) TELEPHONE: 0181-9752000
 (B) TELEFAX: 0181-9756294
 (C) TELEX:

15

(2) INFORMATION FOR SEQ ID NO:1:

20 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2032 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

| | | |
|----|---|------|
| | CCACTTTGAC ACGGCCCTC CCTTGTGACC TGAGGGCAGG TCCCCACTCT GTCCTGGCAG | 60 |
| | GAGCGCATGG GCGAGTGTCT GCAGCGCAGG GGCACCAAGT TCGTACTCAC ATCCATCAAC | 120 |
| 35 | AACATGGCCG CCTTCCTCAT GGCTGCCCTC GTTCCCATCC CTGCGCTGCG AGCCTTCTCC | 180 |
| | CTACAGGCGG CCATAGTGGT TGGCTGCACC TTTGTAGCCG TGATGCTTGT CTTCCCAGCC | 240 |
| | ATCCTCAGCC TGGACCTACG GCGGCGCCAC TGCCAGCGCC TTGATGTGCT CTGCTGCTTC | 300 |
| 40 | TCCAGTCCCT GCTCTGCTCA GGTGATTCAG ATCCTGCCCC AGGAGCTGGG GGACGGGACA | 360 |
| | GTACCAAGTG GCATTGCCCA CCTCACTGCC ACAGTTCAAG CCTTTACCCA CTGTGAAGCC | 420 |
| | AGCAGCCAGC ATGTGGTCAC CATCCTGCCT CCCCAGGCC ACCTGGTGCC CCCACCTTCT | 480 |
| | GACCCACTGG GCTCTGAGCT CTTAGCCCT GGAGGGTCCA CACGGGACCT TCTAGGCCAG | 540 |
| 45 | GAGGAGGAGA CAAGGCAGAA GGCAGCCTGC AAGTCCCTGC CCTGTGCCCG CTGGAATCTT | 600 |
| | GCCCATTTCG CCCGCTATCA GTTGCCCCG TTGCTGCTCC AGTCACATGC CAAGGCCATC | 660 |
| | GTGCTGGTGC TCTTTGGTGC TCTTCTGGGC CTGAGCCTCT ACGGAGCCAC CTTGGTGCAA | 720 |
| | GACGGCCTGG CCTGACGGA TGTGGTGCTT CGGGGCACCA AGGAGCATGC CTTCTGAGC | 780 |
| 50 | GCCCAGCTCA GGTACTTCTC CCTGTACGAG GTGGCCCTGG TGACCCAGGG TGGETTTGAC | 840 |
| | TACGCCCACT CCAACGCGC CCTCTTTGAT CTGCACCAGC GCTTCAGTTC CCTCAAGGCG | 900 |
| | GTGCTGCCCC CACCGGCCAC CCAGGCACCC CGCACCTGGC TGCACTATTA CCGCAACTGG | 960 |
| | CTACAGGGAA TCCAGGCTGC CTTTGACCAG GACTGGGCTT CTGGGCGCAT CACCGGCCAC | 1020 |

55

5 TCGTACCGCA ATGGCTCTGA GGATGGGGCC CTGGCCTACA AGCTGCTCAT CCAGACTGGA 1080
 GACGCCCAGG AGCCTCTGGA TTTCAGCCAG CTGACCACAA GGAAGCTGGT GGACAGAGAG 1140
 GGACTGATTC CACCCGAGCT CTTCTACATG GGGCTGACCG TGTGGGTGAG CAGTGACCCC 1200
 CTGGGTCTGG CAGCCTCACA GGCCAATTC TACCCCCAC CTCCTGAATG GCTGCACGAC 1260
 10 AAATACGACA CCACGGGGGA GAACCTTCGC ATCCCGCCAG CTCAGCCCTT GGAGTTTGCC 1320
 CAGTTCCCTT TCCTGCTGCG TGGCCTCCAG AAGACTGCAG ACTTTGTGGA GGCCATCGAG 1380
 GGGGCCCGGG CAGCATGCGC AGAGGCCGGC CAGGCTGGGG TGCACGCCTA CCCAGCGGC 1440
 TCCCCCTTCC TCTTCTGGA ACAGTATCTG GGCTGCGGC GCTGCTTCTT GCTGGCCGTC 1500
 15 TGCATCCTGC TGGTGTGCAC TTCTCTGTC TGTGCTCTGC TGCTCCTCAA CCCCTGGATG 1560
 GCTGGCCTCA TAGTGAGTGC TTGCAGGAGT GGGGACAGAG ACACCCACC CTCCCTGCC 1620
 CAGCCTGTCA TCCCTCTGC CAGGAGCCCT CTGTAGAGCC TGTCTCCCTC AGGTGCTGGT 1680
 CCTGGCGATG ATGACAGTGG AACTCTTTGG TATCATGGGA TCCCTGGACA TCAAGCTGAG 1740
 20 TGCCATCCCC GTGGTGATCC TTGTGGCTC TGTAGGCATT GGCCTTGAGT TCACAGTCCA 1800
 CGTGGCTCTG GTGAGCACGG GCATCCCGGG GAGGGACCAA TCAGCTGATT CAGTATTCAA 1860
 CACATATTGT TCAAGCCCTT ACTATGTGCT AGGTACTATT TAAGAATTG GGCTGGGTGG 1920
 ACGTGGTGGC TCATTCTGT AGTCCAGCG CTTTGGGAGG CCGAGGCGGG TGGATACCTG 1980
 25 AGGTAGGAAG TTCGAGACCA GCCTGGCCAA CATGGTGAAG CCCTTGTCTT TA 2032

(2) INFORMATION FOR SEQ ID NO:2:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 529 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 35 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

40 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

no. 491 — Met Gly Glu Cys Leu Gln Arg Thr Gly Thr Ser Val Val Leu Thr Ser
 1 5 10 15
 45 Ile Asn Asn Met Ala Ala Phe Leu Met Ala Ala Leu Val Pro Ile Pro
 20 25 30
 Ala Leu Arg Ala Phe Ser Leu Gln Ala Ala Ile Val Val Gly Cys Thr
 35 40 45
 50 Phe Val Ala Val Met Leu Val Phe Pro Ala Ile Leu Ser Leu Asp Leu
 50 55 60
 Arg Arg Arg His Cys Gln Arg Leu Asp Val Leu Cys Cys Phe Ser Ser

55

5 65 70 75 80
 Pro Cys Ser Ala Gln Val Ile Gln Ile Leu Pro Gln Glu Leu Gly Asp
 85 90 95
 Gly Thr Val Pro Val Gly Ile Ala His Leu Thr Ala Thr Val Gln Ala
 10 100 105 110
 Phe Thr His Cys Glu Ala Ser Ser Gln His Val Val Thr Ile Leu Pro
 115 120 125
 Pro Gln Ala His Leu Val Pro Pro Pro Ser Asp Pro Leu Gly Ser Glu
 15 130 135 140
 Leu Phe Ser Pro Gly Gly Ser Thr Arg Asp Leu Leu Gly Gln Gly Glu
 145 150 155 160
 Glu Thr Arg Gln Lys Ala Ala Cys Lys Ser Leu Pro Cys Ala Arg Trp
 20 165 170 175
 Asn Leu Ala His Phe Ala Arg Tyr Gln Phe Ala Pro Leu Leu Leu Gln
 180 185 190
 Ser His Ala Lys Ala Ile Val Leu Val Leu Phe Gly Ala Leu Leu Gly
 25 195 200 205
 Leu Ser Leu Tyr Gly Ala Thr Leu Val Gln Asp Gly Leu Ala Leu Thr
 210 215 220
 Asp Val Val Pro Arg Gly Thr Lys Glu His Ala Phe Leu Ser Ala Gln
 30 225 230 235 240
 Leu Arg Tyr Phe Ser Leu Tyr Glu Val Ala Leu Val Thr Gln Gly Gly
 245 250 255
 Phe Asp Tyr Ala His Ser Gln Arg Ala Leu Phe Asp Leu His Gln Arg
 35 260 265 270
 Phe Ser Ser Leu Lys Ala Val Leu Pro Pro Pro Ala Thr Gln Ala Pro
 275 280 285
 Arg Thr Trp Leu His Tyr Tyr Arg Asn Trp Leu Gln Gly Ile Gln Ala
 40 290 295 300
 Ala Phe Asp Gln Asp Trp Ala Ser Gly Arg Ile Thr Arg His Ser Tyr
 305 310 315 320
 Arg Asn Gly Ser Glu Asp Gly Ala Leu Ala Tyr Lys Leu Leu Ile Gln
 45 325 330 335
 Thr Gly Asp Ala Gln Glu Pro Leu Asp Phe Ser Gln Leu Thr Thr Arg
 340 345 350
 Lys Leu Val Asp Arg Glu Gly Leu Ile Pro Pro Glu Leu Phe Tyr Met
 50 355 360 365
 Gly Leu Thr Val Trp Val Ser Ser Asp Pro Leu Gly Leu Ala Ala Ser
 370 375 380

5 Gln Ala Asn Phe Tyr Pro Pro Pro Glu Trp Leu His Asp Lys Tyr
 385 390 395 400
 X Asp Thr Thr Gly Glu Asn Leu Arg Ile Pro Pro Ala Gln Pro Leu Glu
 405 410 415
 10 Phe Ala Gln Phe Pro Phe Leu Leu Arg Gly Leu Gln Lys Thr Ala Asp
 420 425 430
 Phe Val Glu Ala Ile Glu Gly Ala Arg Ala Ala Cys Ala Glu Ala Gly
 435 440 445
 15 Gln Ala Gly Val His Ala Tyr Pro Ser Gly Ser Pro Phe Leu Phe Trp
 450 455 460
 Glu Gln Tyr Leu Gly Leu Arg Arg Cys Phe Leu Leu Ala Val Cys Ile
 465 470 475 480
 20 Leu Leu Val Cys Thr Phe Leu Val Cys Ala Leu Leu Leu Leu Asn Pro
 485 490 495
 Q Trp Met Ala Gly Leu Ile Val Ser Ala Cys Arg Ser Gly Asp Arg Asp
 500 505 510
 25 Thr Pro Pro Phe Pro Ala Gln Pro Val Ile Pro Pro Ala Arg Ser Pro
 515 520 525
 Leu

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- 35 (A) LENGTH: 138 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 40 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

45 CTGTCCTGGC AGGAGCGCAT GGGCGAGTGT CTGCAGCGCA CGGGCACCAG TGTCGTACTC 60
 ACATCCATCA ACAACATGGC CGCCTTCTC ATGGCTGCC TCGTTCCCAT CCCTGCGCTG 120
 50 CGAGCCTTCT CCCTACAG 138

(2) INFORMATION FOR SEQ ID NO:4:

5 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 46 base pairs
 (B) TYPE: nucleic acid
 10 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

| | | | | | | | | | | | | | | | | |
|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| | Leu | Ser | Trp | Gln | Glu | Arg | Met | Gly | Glu | Cys | Leu | Gln | Arg | Thr | Gly | Thr |
| 20 | 1 | | | | 5 | | | | 10 | | | | | 15 | | |
| | Ser | Val | Val | Leu | Thr | Ser | Ile | Asn | Asn | Met | Ala | Ala | Phe | Leu | Met | Ala |
| | | | | 20 | | | | 25 | | | | | 30 | | | |
| | Ala | Leu | Val | Pro | Ile | Pro | Ala | Leu | Arg | Ala | Phe | Ser | Leu | Gln | | |
| 25 | | | 35 | | | | | 40 | | | | | 45 | | | |

30 Claims

1. An isolated polypeptide comprising an amino acid sequence which has at least 92% identity to the amino acid sequence of SEQ ID NO:2 over the entire length of of SEQ ID NO:2.
- 35 2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 98% identity.
3. The polypeptide as claimed in claim 1 comprising the amino acid sequence of SEQ ID NO:2.
- 40 4. The isolated polypeptide of SEQ ID NO:2.
5. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 92% identity to the amino acid sequence of SEQ ID NO:2, over the entire length of SEQ ID NO:2; or a nucleotide sequence complementary to said isolated polynucleotide.
- 45 6. An isolated polynucleotide comprising a nucleotide sequence that has at least 90% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2, over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.
- 50 7. An isolated polynucleotide which comprises a nucleotide sequence which has at least 90% identity to that of SEQ ID NO: 1 over the entire length of SEQ ID NO: 1; or a nucleotide sequence complementary to said isolated polynucleotide.
8. The isolated polynucleotide as claimed in any one of claims 5 to 7 in which the identity is at least 95%.
- 55 9. An isolated polynucleotide selected from:
 - (a) a polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2;
 - (b) the polynucleotide of SEQ ID NO: 1; and

(c) a polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof;

or a nucleotide sequence complementary to said isolated polynucleotide

10. An expression system comprising a polynucleotide capable of producing a polypeptide of claim 1 when said expression system is present in a compatible host cell.

11. A host cell comprising the expression system of claim 15 or a membrane thereof expressing the polypeptide of claim 1.

12. A process for producing a polypeptide of claim 1 comprising culturing a host cell of claim 11 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

13. An antibody immunospecific for the polypeptide of claim 1.

14. A method for screening to identify compounds which stimulate or which inhibit the function of the polypeptide of claim 1 which comprises a method selected from the group consisting of:

(a) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound;

(b) measuring the binding of a candidate compound to the polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competitor;

(c) testing whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide;

(d) mixing a candidate compound with a solution containing a polypeptide of claim 1, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a standard; or

(e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and said polypeptide in cells, using for instance, an ELISA assay.

15. An agonist or antagonist to the polypeptide of claims 1 to 4.

16. A compound which is:

(a) an agonist or antagonist to the polypeptide of claims 1 to 4;

(b) isolated polynucleotide of claims 5 to 9; or

(c) a nucleic acid molecule that modulates the expression of the nucleotide sequence encoding the polypeptide of claim 1;

for use in therapy.

17. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of the polypeptide of claim 1 in a subject comprising:

(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said polypeptide in the genome of said subject; and/or

(b) analyzing for the presence or amount of said polypeptide expression in a sample derived from said subject.

18. An isolated polynucleotide selected from the group consisting of:

(a) an isolated polynucleotide comprising a nucleotide sequence which has at least 75% identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3;

(b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO:3;

(c) the polynucleotide of SEQ ID NO:3; or

(d) an isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide which has at least 80% identity to the amino acid sequence of SEQ ID NO:4, over the entire length of the sequence of SEQ ID NO:4.

19. A polypeptide selected from the group consisting of:

- (a) a polypeptide which comprises an amino acid sequence which has at least 80% identity to the sequence of SEQ ID NO:4 over the entire length of the sequence of SEQ ID NO:4;
- (b) a polypeptide in which the amino acid sequence has at least 80% identity to the amino acid sequence of SEQ ID NO:4 over the entire length of the sequence of SEQ ID NO:4;
- (c) a polypeptide which comprises the amino acid sequence of SEQ ID NO:4;
- (d) a polypeptide which is the polypeptide of SEQ ID NO:4; or
- (e) a polypeptide which is encoded by a polynucleotide comprising the sequence contained in SEQ ID NO:3.

Beställare
PATPAN

Ärende
se991784

Dokument
EP 0879888A3 I

Antal sidor utöver denna
4

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 879 888 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:

14.07.1999 Bulletin 1999/28

(43) Date of publication A2:

25.11.1998 Bulletin 1998/48

(21) Application number: **98303994.2**

(22) Date of filing: **20.05.1998**

(51) Int Cl.⁶: **C12N 15/12, C07K 14/705,
C12Q 1/68, A61K 31/70,
A61K 38/17, G01N 33/50,
G01N 33/68**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

Designated Extension States:

AL LT LV MK RO SI

• Barnes, Michael R., SmithKline Beecham Pharm.
Harlow, Essex CM19 5AW (GB)

• Testa, Tania Tamson,
SmithKline Beecham Pharm.
Harlow, Essex CM19 5AW (GB)

(30) Priority: **23.05.1997 GB 9710752**

19.03.1998 GB 9805954

(74) Representative:

**Crump, Julian Richard John et al
FJ Cleveland,
40-43 Chancery Lane
London WC2A 1JQ (GB)**

(71) Applicant: **SMITHKLINE BEECHAM PLC
Brentford, Middlesex TW8 9EP (GB)**

(72) Inventors:

• Kelsell, David P., SmithKline Beecham Pharm.
Harlow, Essex CM19 5AW (GB)

(54) **Patched-2 polypeptides and polynucleotides and methods for their production**

(57) Patched-2 polypeptides and polynucleotides
and methods for producing such polypeptides by recom-

binant techniques are disclosed. Also disclosed are
methods for utilizing Patched-2 polypeptides and poly-
nucleotides in therapy, and diagnostic assays for such.

EP 0 879 888 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int.CI.6) |
|-----------|---|-------------------|---|
| P,X | TAKABATAKE T ET AL: "Hedgehog and patched gene expression in adult ocular tissues" FEBS LETTERS., vol. 410, 30 June 1997, pages 485-489, XP002101427 Murien ptc2: 92.0% identical in 503aa / 88.8% identical in 1527bp see section 3.1 and figure 2 * figure 2 * | 1-19 | C12N15/12 C07K14/705 C12Q1/68 A61K31/70 A61K38/17 G01N33/50 G01N33/68 |
| P,X, D | MOTOYAMA J ET AL: "Ptch2, a second mouse Patched gene is co-expressed with Sonic hedgehog" NAT. GENET., vol. 18, February 1998, pages 104-106, XP002101696 Murine ptc2: 92.0% identity in 503aa / 88.8% identity in 1527bp * figure 1 * | 1-19 | |
| A | WO 96 11260 A (UNIV LELAND STANFORD JUNIOR) 18 April 1996 --- -/-- | | TECHNICAL FIELDS SEARCHED (Int.CI.6) C12N C07K C12Q A61K G01N |

INCOMPLETE SEARCH

The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.

Claims searched completely :

Claims searched incompletely :

Claims not searched :

Reason for the limitation of the search:

Claims 15 and 16, relating to an agonist or an antagonist to the polypeptide of claims 1 to 4, could not be searched completely as their subject-matter was not sufficiently characterised.

Place of search

THE HAGUE

Date of completion of the search

3 May 1999

Examiner

Lonnoy, O

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons
A : member of the same patent family, corresponding document

EP 0 879 888 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 98 30 3994

| DOCUMENTS CONSIDERED TO BE RELEVANT | | | CLASSIFICATION OF THE APPLICATION (Int.Cl.6) |
|-------------------------------------|---|-------------------|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | |
| A | CONCORDET JP ET AL: "Spatial regulation of a zebrafish patched homologue reflects the roles of sonic hedgehog and protein kinase A in neural tube and somite patterning." DEVELOPMENT, vol. 122, no. 9, September 1996, pages 2835-2846, XP002101697 ----- | | |
| | | | TECHNICAL FIELDS SEARCHED (Int.Cl.6) |
| | | | |
| | | | |

EPO FORM 1503 03 87 (P04C10)

EP 0 879 888 A3

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 30 3994

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-05-1999

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO 9611260 A | 18-04-1996 | AU 4001195 A | 02-05-1996 |
| | | EP 0804548 A | 05-11-1997 |
| | | JP 10507349 T | 21-07-1998 |
| | | US 5837538 A | 17-11-1998 |

EPO FORM P0459

For more details about this annex: see Official Journal of the European Patent Office, No. 12/82